Scott Jennings Reacts to Ana Navarro’s R-Rated Rant About Robert De Niro and...
Out to Lynch: ‘Historian’ Heather Cox Richardson Tells Jim Acosta UFC ‘Impulse’ Tied...
Miles Off: ‘Anonymous’ Writer Says UFC Freedom 250 Event Was Humiliating Image of...
Phallus in Chains: The View’s Sunny Hostin Says Claims Michelle Obama Is a...
How Will UK Enforce Its Ban on Social Media for Kids Under 16?
Judge Dismisses Lawsuit by Nonbinary Park Ranger Fired for Hanging Trans Flag in...
CBS News: Veteran Desperately Urging ICE to Release His Wife; 'It Rips My...
Can't You FEEL the Love? Obamas Unveil Commissioned Portrait of Themselves at Presidential...
Sister of MI Senate Candidate Charged With Aggravated Battery at Anti-ICE Protest
California Fault Lyin’: Gavin Newsom Blames Trump for DOJ Investigation Started Under Anot...
Pro-Trans Doctor Denies Teenage Girls Are Having Healthy Breasts Removed, Just Teenage Boy...
Report: Graham Platner Mocked Teen’s Suicide Attempt on Reddit
Knicks 'Fans' Destroy Cab Driver's Livelihood in Mamdani's NYC — Immigrant Ruined After...
Bombshell Betrayal: Spencer Pratt Teams Up With Karen Bass’ Brother to Sue Her...
Politburo Posse Poses Proudly for Trump’s World Cup Win None of Them Helped...

Christina Pushaw busts the AP for acknowledging a COVID treatment fact they shamed Ron DeSantis for pointing out just a few months ago

Yesterday, the Associated Press’ Matthew Perrone reported a possible setback for a couple of COVID19 treatments, including Regeneron.

Advertisement

More from the AP:

As strained U.S. hospitals brace for a new surge of COVID-19 cases caused by the fast-spreading omicron variant, doctors are warning of yet another challenge: the two standard drugs they’ve used to fight infections are unlikely to work against the new strain.

For more than a year antibody drugs from Regeneron and Eli Lilly have been the go-to treatments for early COVID-19, thanks to their ability to head off severe disease and keep patients out of the hospital.

But both drugmakers recently warned that laboratory testing suggests their therapies will be much less potent against omicron, which contains dozens of mutations that make it harder for antibodies to attack the virus. And while the companies say they can quickly develop new omicron-targeting antibodies, those aren’t expected to launch for at least several months.

The fact that Regeneron may not be as effective against the omicron variant as it’s been against others is noteworthy enough. But Gov. Ron DeSantis’ press secretary Christina Pushaw finds something else noteworthy, too:

Things sure have changed, haven’t they? Recall this past August, when the AP was entertaining the idea that DeSantis was promoting sketchy Regeneron in some kind of quid pro quo scheme because one of his top donors had invested money in Regeneron, making DeSantis shady AF and not to be trusted.

Advertisement

Pushaw called out the AP then.

Just like she’s calling out the AP now.

We’ve got whiplash.

And Pushaw’s got one last question for the AP:

Join the conversation as a VIP Member

Recommended

Trending on Twitchy Videos

Advertisement
Advertisement
Advertisement